Emibetuzumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Emibetuzumab (LY2875358) 是一种人源化二价 MET 抗体 (IgG4 型)。Emibetuzumab 具有较高的中和与内化活性，能有效抑制 HGF 依赖性和非依赖性 MET 通路的激活和肿瘤生长。Emibetuzumab 可用于癌症的研究。

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.

Emibetuzumab (LY2875358) (100 nmol/L; 6 days) inhibits HGF-stimulated proliferation of H596.Cell Proliferation Assay Cell Line:H596 cells (HGF-stimulated) Concentration:100 nmol/L Incubation Time:6 days Result:Suppressed cell proliferation.

Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice.Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice.Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models.Animal Model:Athymic nude mice (U87MG tumor xenograft model).Dosage:10 mg/kg Administration: Intravenous injection, once a week for 5 weeks.Result:Demonstrated a significant inhibition of tumor growth.Animal Model:Athymic nude mice (MKN45 xenograft tumor model).Dosage:10 or 20 mg/kg Administration:Intravenous injection, single.Result:Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.Animal Model:Athymic nude mice (MET-amplified xenograft mouse tumor models).Dosage:10 mg/kg Administration:Intravenous injection, once a week for 3, 5 or 6 weeks. Result:Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.

——

Angiogenesis

c-Met/HGFR

c-Met/HGFR

——

——

1365287-97-3

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years